sphingosine-kinase and Insulinoma

sphingosine-kinase has been researched along with Insulinoma* in 2 studies

Other Studies

2 other study(ies) available for sphingosine-kinase and Insulinoma

ArticleYear
Sphingosine kinase 1 knockdown reduces insulin synthesis and secretion in a rat insulinoma cell line.
    Archives of biochemistry and biophysics, 2012, Feb-01, Volume: 518, Issue:1

    To evaluate the role of sphingosine kinase 1 (SphK1) in insulin secretion, we used stable transfection to knock down the expression of the Sphk1 gene in the rat insulinoma INS-1 832/13 cell line. Cell lines with lowered Sphk1 mRNA expression and SphK1 enzyme activity (SK11 and SK14) exhibited lowered glucose- and 2-aminobicyclo[2,2,1]heptane-2-carboxylic acid (BCH) plus glutamine-stimulated insulin release and low insulin content associated with decreases in the mRNA of the insulin 1 gene. Overexpression of the rat or human Sphk1 cDNA restored insulin secretion and total insulin content in the SK11 cell line, but not in the SK14 cell line. The Sphk1 cDNA-transfected SK14 cell line expressed significantly less SphK1 activity than the Sphk1 cDNA-transfected SK11 cells suggesting that the shRNA targeting SK14 was more effective in silencing the exogenous rat Sphk1 mRNA. The results indicate that SphK1 activity is important for insulin synthesis and secretion.

    Topics: Animals; Cell Line, Tumor; Enzyme Inhibitors; Gene Knockdown Techniques; Humans; Insulin; Insulin Secretion; Insulinoma; Phosphotransferases (Alcohol Group Acceptor); Rats; Sphingosine

2012
Sphingosine 1-phosphate (S1P) regulates glucose-stimulated insulin secretion in pancreatic beta cells.
    The Journal of biological chemistry, 2012, Apr-13, Volume: 287, Issue:16

    Recent studies suggest that sphingolipid metabolism is altered during type 2 diabetes. Increased levels of the sphingolipid ceramide are associated with insulin resistance. However, a role for sphingolipids in pancreatic beta cell function, or insulin production, and release remains to be established. Our studies in MIN6 cells and mouse pancreatic islets demonstrate that glucose stimulates an intracellular rise in the sphingolipid, sphingosine 1-phosphate (S1P), whereas the levels of ceramide and sphingomyelin remain unchanged. The increase in S1P levels by glucose is due to activation of sphingosine kinase 2 (SphK2). Interestingly, rises in S1P correlate with increased glucose-stimulated insulin secretion (GSIS). Decreasing S1P levels by treatment of MIN6 cells or primary islets with the sphingosine kinase inhibitor reduces GSIS. Moreover, knockdown of SphK2 alone results in decreased GSIS, whereas knockdown of the S1P phosphatase, Sgpp1, leads to a rise in GSIS. Treatment of mice with the sphingosine kinase inhibitor impairs glucose disposal due to decreased plasma insulin levels. Altogether, our data suggest that glucose activates SphK2 in pancreatic beta cells leading to a rise in S1P levels, which is important for GSIS.

    Topics: Animals; Cell Line, Tumor; Glucose; Glucose Intolerance; Glucose Tolerance Test; Injections, Intraperitoneal; Insulin; Insulin Secretion; Insulin-Secreting Cells; Insulinoma; Lysophospholipids; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Phosphoric Monoester Hydrolases; Phosphotransferases (Alcohol Group Acceptor); RNA, Small Interfering; Sphingosine

2012